TP53 and neoplasm: Approaches for targeting p53 can be summarized as follows: first, compounds such as idasanutlin (RG7388) and RG7112 were developed to prevent degradation of wild-type p53 by blocking p53-MDM2 interactions,369,370 thus maintaining their ability to suppress tumor formation.